Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Three-year overall survival (OS) and GVHD-free, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback